Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

A potential breakthrough in spinal cord and optic nerve injury treatment

Click Here to Download the Full Report This is third-party provided content issued on behalf of NurExone Biologic Inc., please see full disclaimer here .

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. In a June 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the U.S. Food and Drug Administration (FDA) designated Axsome Therapeutics...

XPhyto: Readying a Next-Generation PCR Test Kit for Marquis Sales Opportunities

Ambitious start-ups are always delighted when they receive a blitz of media coverage after announcing a technological breakthrough. It validates the credibility of the technology, boosts morale among employees and alerts the market to the company’s potentia...

XPhyto Announces a PCR Testing Breakthrough

It’s the technological breakthrough that the world has been waiting for. A small Canadian life sciences company, XPhyto Therapeutics Corp. ( CSE:XPHY ) (FSE:4XT), has just announced its ability to significantly speed up testing for COVID-19 in an...

Alzheimer’s Breakthrough: Why the Experts are Betting on NervGen

It's the disease that most of us regard with the greatest dread – especially since nearly one in every three people will eventually be afflicted. This is why a breakthrough pharmaceutical drug for Alzheimer’s disease would not only be a godsend to society,...

XPhyto to Announce PCR Test Kit Final Validation Results

It could be the Holy Grail of COVID-19 testing. Remarkably, a small Canadian life sciences company, XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) is becoming a front-runner in the race to bring this breakthrough technology to market – starting with Germany. This ref...

BHP Joins Forces with Prospect Generator to Explore Mexican Copper Project

In this exclusive interview, Maurice Jackson of Proven and Probable sits down with Dr. John-Mark Staude the President and CEO of Riverside Resources (TSX.V: RRI | OTCQB: RVSDF) to announce a major breakthrough for shareholders. BHP and Riverside Resources are joining ...

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). This morning orphan lun...

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...

Atomera: When Will Revenues Start?

Atomera Inc. (ATOM:NASDAQ) reported earnings on Wednesday after the close. The numbers are rather meaningless for Atomera as they are pre-revenue. What investors are looking for is clues to when revenues will start and the likelihood that customers will adopt Atomera's...
1 2 3 4 5 6 7 8 9 10 ...